Search

Your search keyword '"Sadetzki S"' showing total 289 results
Start Over Author "Sadetzki S"
289 results on '"Sadetzki S"'

2. Wireless phone use in childhood and adolescence and neuroepithelial brain tumours: Results from the international MOBI-Kids study

Author

IRAS OH Epidemiology Chemical Agents, dIRAS RA-2, Castaño-Vinyals, G, Sadetzki, S, Vermeulen, R, Momoli, F, Kundi, M, Merletti, F, Maslanyj, M, Calderon, C, Wiart, J, Lee, A-K, Taki, M, Sim, M, Armstrong, B, Benke, G, Schattner, R, Hutter, H-P, Krewski, D, Mohipp, C, Ritvo, P, Spinelli, J, Lacour, B, Remen, T, Radon, K, Weinmann, T, Petridou, E Th, Moschovi, M, Pourtsidis, A, Oikonomou, K, Kanavidis, P, Bouka, E, Dikshit, R, Nagrani, R, Chetrit, A, Bruchim, R, Maule, M, Migliore, E, Filippini, G, Miligi, L, Mattioli, S, Kojimahara, N, Yamaguchi, N, Ha, M, Choi, K, Kromhout, H, Goedhart, G, 't Mannetje, A, Eng, A, Langer, C E, Alguacil, J, Aragonés, N, Morales-Suárez-Varela, M, Badia, F, Albert, A, Carretero, G, Cardis, E, IRAS OH Epidemiology Chemical Agents, dIRAS RA-2, Castaño-Vinyals, G, Sadetzki, S, Vermeulen, R, Momoli, F, Kundi, M, Merletti, F, Maslanyj, M, Calderon, C, Wiart, J, Lee, A-K, Taki, M, Sim, M, Armstrong, B, Benke, G, Schattner, R, Hutter, H-P, Krewski, D, Mohipp, C, Ritvo, P, Spinelli, J, Lacour, B, Remen, T, Radon, K, Weinmann, T, Petridou, E Th, Moschovi, M, Pourtsidis, A, Oikonomou, K, Kanavidis, P, Bouka, E, Dikshit, R, Nagrani, R, Chetrit, A, Bruchim, R, Maule, M, Migliore, E, Filippini, G, Miligi, L, Mattioli, S, Kojimahara, N, Yamaguchi, N, Ha, M, Choi, K, Kromhout, H, Goedhart, G, 't Mannetje, A, Eng, A, Langer, C E, Alguacil, J, Aragonés, N, Morales-Suárez-Varela, M, Badia, F, Albert, A, Carretero, G, and Cardis, E

Published
2022

3. Diagnostic radiological examinations and risk of intracranial tumours in adults-findings from the Interphone Study.

Author

Auvinen, A, Cardis, E, Blettner, M, Moissonnier, M, Sadetzki, S, Giles, G, Johansen, C, Swerdlow, A, Cook, A, Fleming, S, Berg-Beckhoff, G, Iavarone, I, Parent, M-E, Woodward, A, Tynes, T, McBride, M, Krewski, D, Feychting, M, Takebayashi, T, Armstrong, B, Hours, M, Siemiatycki, J, Lagorio, S, Larsen, SB, Schoemaker, M, Klaeboe, L, Lönn, S, Schüz, J, INTERPHONE study group, Auvinen, A, Cardis, E, Blettner, M, Moissonnier, M, Sadetzki, S, Giles, G, Johansen, C, Swerdlow, A, Cook, A, Fleming, S, Berg-Beckhoff, G, Iavarone, I, Parent, M-E, Woodward, A, Tynes, T, McBride, M, Krewski, D, Feychting, M, Takebayashi, T, Armstrong, B, Hours, M, Siemiatycki, J, Lagorio, S, Larsen, SB, Schoemaker, M, Klaeboe, L, Lönn, S, Schüz, J, and INTERPHONE study group

Abstract

BACKGROUND: Exposure to high doses of ionizing radiation is among the few well-established brain tumour risk factors. We used data from the Interphone study to evaluate the effects of exposure to low-dose radiation from diagnostic radiological examinations on glioma, meningioma and acoustic neuroma risk. METHODS: Brain tumour cases (2644 gliomas, 2236 meningiomas, 1083 neuromas) diagnosed in 2000-02 were identified through hospitals in 13 countries, and 6068 controls (population-based controls in most centres) were included in the analysis. Participation across all centres was 64% for glioma cases, 78% for meningioma cases, 82% for acoustic neuroma cases and 53% for controls. Information on previous diagnostic radiological examinations was obtained by interviews, including the frequency, timing and indication for the examinations. Typical brain doses per type of examination were estimated based on the literature. Examinations within the 5 years before the index date were excluded from the dose estimation. Adjusted odds ratios were estimated using conditional logistic regression. RESULTS: No materially or consistently increased odds ratios for glioma, meningioma or acoustic neuroma were found for any specific type of examination, including computed tomography of the head and cerebral angiography. The only indication of an elevated risk was an increasing trend in risk of meningioma with the number of isotope scans, but no such trends for other examinations were observed. No gradient was found in risk with estimated brain dose. Age at exposure did not substantially modify the findings. Sensitivity analyses gave results consistent with the main analysis. CONCLUSIONS: There was no consistent evidence for increased risks of brain tumours with X-ray examinations, although error from selection and recall bias cannot be completely excluded. A cautious interpretation is warranted for the observed association between isotope scans and meningioma.

Published
2022

5. Wireless phone use in childhood and adolescence and neuroepithelial brain tumours: Results from the international MOBI-Kids study

Author

Castaño-Vinyals, G., primary, Sadetzki, S., additional, Vermeulen, R., additional, Momoli, F., additional, Kundi, M., additional, Merletti, F., additional, Maslanyj, M., additional, Calderon, C., additional, Wiart, J., additional, Lee, A.-K., additional, Taki, M., additional, Sim, M., additional, Armstrong, B., additional, Benke, G., additional, Schattner, R., additional, Hutter, H.-P., additional, Krewski, D., additional, Mohipp, C., additional, Ritvo, P., additional, Spinelli, J., additional, Lacour, B., additional, Remen, T., additional, Radon, K., additional, Weinmann, T., additional, Petridou, E.Th., additional, Moschovi, M., additional, Pourtsidis, A., additional, Oikonomou, K., additional, Kanavidis, P., additional, Bouka, E., additional, Dikshit, R., additional, Nagrani, R., additional, Chetrit, A., additional, Bruchim, R., additional, Maule, M., additional, Migliore, E., additional, Filippini, G., additional, Miligi, L., additional, Mattioli, S., additional, Kojimahara, N., additional, Yamaguchi, N., additional, Ha, M., additional, Choi, K., additional, Kromhout, H., additional, Goedhart, G., additional, 't Mannetje, A., additional, Eng, A., additional, Langer, C.E., additional, Alguacil, J., additional, Aragonés, N., additional, Morales-Suárez-Varela, M., additional, Badia, F., additional, Albert, A., additional, Carretero, G., additional, and Cardis, E., additional

Published
2022
Full Text
View/download PDF

7. Determinants of mobile phone output power in a multinational study: implications for exposure assessment

Author

Vrijheid, M, Mann, S, Vecchia, P, Wiart, J, Taki, M, Ardoino, L, Armstrong, B K, Auvinen, A, Bédard, D, Berg-Beckhoff, G, Brown, J, Chetrit, A, Collatz-Christensen, H, Combalot, E, Cook, A, Deltour, I, Feychting, M, Giles, G G, Hepworth, S J, Hours, M, Iavarone, I, Johansen, C, Krewski, D, Kurttio, P, Lagorio, S, Lönn, S, McBride, M, Montestrucq, L, Parslow, R C, Sadetzki, S, Schüz, J, Tynes, T, Woodward, A, and Cardis, E

Published
2009

8. Validation of Short Term Recall of Mobile Phone Use for the Interphone Study

Author

Interphone Study Group, Vrijheid, M., Cardis, E., Armstrong, B. K., Auvinen, A., Berg, G., Blaasaas, K. G., Brown, J., Carroll, M., Chetrit, A., Christensen, H. C., Deltour, I., Feychting, M., Giles, G. G., Hepworth, S. J., Hours, M., Iavarone, I., Johansen, C., Klæboe, L., Kurttio, P., Lagorio, S., Lönn, S., McKinney, P. A., Montestrucq, L., Parslow, R. C., Richardson, L., Sadetzki, S., Salminen, T., Schüz, J., Tynes, T., and Woodward, A.

Published
2006
Full Text
View/download PDF

11. Clinical presentation of young people (10–24 years old) with brain tumors: results from the international MOBI-Kids study

Author

Zumel-Marne, A. Kundi, M. Castaño-Vinyals, G. Alguacil, J. Petridou, E.T. Georgakis, M.K. Morales-Suárez-Varela, M. Sadetzki, S. Piro, S. Nagrani, R. Filippini, G. Hutter, H.-P. Dikshit, R. Woehrer, A. Maule, M. Weinmann, T. Krewski, D. ′t Mannetje, A. Momoli, F. Lacour, B. Mattioli, S. Spinelli, J.J. Ritvo, P. Remen, T. Kojimahara, N. Eng, A. Thurston, A. Lim, H. Ha, M. Yamaguchi, N. Mohipp, C. Bouka, E. Eastman, C. Vermeulen, R. Kromhout, H. Cardis, E.

Abstract

Introduction: We used data from MOBI-Kids, a 14-country international collaborative case–control study of brain tumors (BTs), to study clinical characteristics of the tumors in older children (10 years or older), adolescents and young adults (up to the age of 24). Methods: Information from clinical records was obtained for 899 BT cases, including signs and symptoms, symptom onset, diagnosis date, tumor type and location. Results: Overall, 64% of all tumors were low-grade, 76% were neuroepithelial tumors and 62% gliomas. There were more males than females among neuroepithelial and embryonal tumor cases, but more females with meningeal tumors. The most frequent locations were cerebellum (22%) and frontal (16%) lobe. The most frequent symptom was headaches (60%), overall, as well as for gliomas, embryonal and ‘non-neuroepithelial’ tumors; it was convulsions/seizures for neuroepithelial tumors other than glioma, and visual signs and symptoms for meningiomas. A cluster analysis showed that headaches and nausea/vomiting was the only combination of symptoms that exceeded a cutoff of 50%, with a joint occurrence of 67%. Overall, the median time from first symptom to diagnosis was 1.42 months (IQR 0.53–4.80); it exceeded 1 year in 12% of cases, though no particular symptom was associated with exceptionally long or short delays. Conclusions: This is the largest clinical epidemiology study of BT in young people conducted so far. Many signs and symptoms were identified, dominated by headaches and nausea/vomiting. Diagnosis was generally rapid but in 12% diagnostic delay exceeded 1 year with none of the symptoms been associated with a distinctly long time until diagnosis. © 2020, The Author(s).

Published
2020

14. Validation of short term recall of mobile phone use for the Interphone study

Author

Vrijheid, M, Cardis, E, Armstrong, B K, Auvinen, A, Berg, G, Blaasaas, K G, Brown, J, Carroll, M, Chetrit, A, Christensen, H C, Deltour, I, Feychting, M, Giles, G G, Hepworth, S J, Hours, M, Iavarone, I, Johansen, C, Klæboe, L, Kurttio, P, Lagorio, S, Lönn, S, McKinney, P A, Montestrucq, L, Parslow, R C, Richardson, L, Sadetzki, S, Salminen, T, Schüz, J, Tynes, T, and Woodward, A

Published
2006

17. Recall of mobile phone usage and laterality in young people: The multinational Mobi-Expo study

Author

Goedhart, G. van Wel, L. Langer, C.E. de Llobet Viladoms, P. Wiart, J. Hours, M. Kromhout, H. Benke, G. Bouka, E. Bruchim, R. Choi, K.-H. Eng, A. Ha, M. Huss, A. Kiyohara, K. Kojimahara, N. Krewski, D. Lacour, B. ‘t Mannetje, A. Maule, M. Migliore, E. Mohipp, C. Momoli, F. Petridou, E.T. Radon, K. Remen, T. Sadetzki, S. Sim, M. Weinmann, T. Cardis, E. Vrijheid, M. Vermeulen, R.

Abstract

Objective: To study recall of mobile phone usage, including laterality and hands-free use, in young people. Methods: Actual mobile phone use was recorded among volunteers aged between 10 and 24 years from 12 countries by the software application XMobiSense and was compared with self-reported mobile phone use at 6 and 18 months after using the application. The application recorded number and duration of voice calls, number of text messages, amount of data transfer, laterality (% of call time the phone was near the right or left side of the head, or neither), and hands-free usage. After data cleaning, 466 participants were available for the main analyses (recorded vs. self-reported phone use after 6 months). Results: Participants were on average 18.6 years old (IQR 15.2-21.8 years). The Spearman correlation coefficients between recorded and self-reported (after 6 months) number and duration of voice calls were 0.68 and 0.65, respectively. Number of calls was on average underestimated by the participants (adjusted geometric mean ratio (GMR) self-report/recorded = 0.52, 95% CI = 0.47-0.58), while duration of calls was overestimated (GMR=1.32, 95%, CI = 1.15-1.52). The ratios significantly differed by country, age, maternal educational level, and level of reported phone use, but not by time of the interview (6 vs. 18 months). Individuals who reported low mobile phone use underestimated their use, while individuals who reported the highest level of phone use were more likely to overestimate their use. Individuals who reported using the phone mainly on the right side of the head used it more on the right (71.1%) than the left (28.9%) side. Self-reported left side users, however, used the phone only slightly more on the left (53.3%) than the right (46.7%) side. Recorded percentage hands-free use (headset, speaker mode, Bluetooth) increased with increasing self-reported frequency of hands-free device usage. Frequent (≥50% of call time) reported headset or speaker mode use corresponded with 17.1% and 17.2% of total call time, respectively, that was recorded as hands-free use. Discussion: These results indicate that young people can recall phone use moderately well, with recall depending on the amount of phone use and participants’ characteristics. The obtained information can be used to calibrate self-reported mobile use to improve estimation of radiofrequency exposure from mobile phones. © 2018 Elsevier Inc.

Published
2018

18. Sex-specific glioma genome-wide association study identifies new risk locus at 3p21.31 in females, and finds sex-differences in risk at 8q24.21.

Author

Ostrom, QT, Kinnersley, B, Wrensch, MR, Eckel-Passow, JE, Armstrong, G, Rice, T, Chen, Y, Wiencke, JK, McCoy, LS, Hansen, HM, Amos, CI, Bernstein, JL, Claus, EB, Il'yasova, D, Johansen, C, Lachance, DH, Lai, RK, Merrell, RT, Olson, SH, Sadetzki, S, Schildkraut, JM, Shete, S, Rubin, JB, Lathia, JD, Berens, ME, Andersson, U, Rajaraman, P, Chanock, SJ, Linet, MS, Wang, Z, Yeager, M, GliomaScan consortium, Houlston, RS, Jenkins, RB, Melin, B, Bondy, ML, Barnholtz-Sloan, JS, Ostrom, QT, Kinnersley, B, Wrensch, MR, Eckel-Passow, JE, Armstrong, G, Rice, T, Chen, Y, Wiencke, JK, McCoy, LS, Hansen, HM, Amos, CI, Bernstein, JL, Claus, EB, Il'yasova, D, Johansen, C, Lachance, DH, Lai, RK, Merrell, RT, Olson, SH, Sadetzki, S, Schildkraut, JM, Shete, S, Rubin, JB, Lathia, JD, Berens, ME, Andersson, U, Rajaraman, P, Chanock, SJ, Linet, MS, Wang, Z, Yeager, M, GliomaScan consortium, Houlston, RS, Jenkins, RB, Melin, B, Bondy, ML, and Barnholtz-Sloan, JS

Abstract

Incidence of glioma is approximately 50% higher in males. Previous analyses have examined exposures related to sex hormones in women as potential protective factors for these tumors, with inconsistent results. Previous glioma genome-wide association studies (GWAS) have not stratified by sex. Potential sex-specific genetic effects were assessed in autosomal SNPs and sex chromosome variants for all glioma, GBM and non-GBM patients using data from four previous glioma GWAS. Datasets were analyzed using sex-stratified logistic regression models and combined using meta-analysis. There were 4,831 male cases, 5,216 male controls, 3,206 female cases and 5,470 female controls. A significant association was detected at rs11979158 (7p11.2) in males only. Association at rs55705857 (8q24.21) was stronger in females than in males. A large region on 3p21.31 was identified with significant association in females only. The identified differences in effect of risk variants do not fully explain the observed incidence difference in glioma by sex.

Published
2018

19. Patterns of cellular phone use among young people in 12 countries: Implications for RF exposure

Author

Langer, C.E. de Llobet, P. Dalmau, A. Wiart, J. Goedhart, G. Hours, M. Benke, G.P. Bouka, E. Bruchim, R. Choi, K.-H. Eng, A. Ha, M. Karalexi, M. Kiyohara, K. Kojimahara, N. Krewski, D. Kromhout, H. Lacour, B. Mannetje, A. Maule, M. Migliore, E. Mohipp, C. Momoli, F. Petridou, E. Radon, K. Remen, T. Sadetzki, S. Sim, M.R. Weinmann, T. Vermeulen, R. Cardis, E. Vrijheid, M.

Abstract

Characterizing exposure to radiofrequency (RF) fields from wireless telecommunications technologies during childhood and adolescence is a research priority in investigating the health effects of RF. The Mobi-Expo study aimed to describe characteristics and determinants of cellular phone use in 534 young people (10–24 years) in 12 countries. The study used a specifically designed software application installed on smartphones to collect data on the use of wireless telecommunications devices within this age group. The role of gender, age, maternal education, calendar period, and country was evaluated through multivariate models mutually adjusting for all variables. Call number and duration were higher among females compared to males (geometric mean (GM) ratio 1.17 and 1.42, respectively), among 20–24 year olds compared to 10–14 year olds (GM ratio 2.09 and 4.40, respectively), and among lowest compared to highest social classes (GM ratio 1.52 and 1.58, respectively). The number of SMS was higher in females (GM ratio 1.46) and the middle age group (15–19 year olds: GM ratio 2.21 compared to 10–14 year olds) and decreased over time. Data use was highest in the oldest age group, whereas Wi-Fi use was highest in the middle age group. Both data and Wi-Fi use increased over time. Large differences in the number and duration of calls, SMS, and data/Wi-Fi use were seen by country, with country and age accounting for up to 50% of the variance. Hands-free and laterality of use did not show significant differences by sex, age, education, study period, or country. Although limited by a convenience sample, these results provide valuable insights to the design, analysis, and interpretation of future epidemiological studies concerning the health effects of exposure resulting from cellular phone use in young people. In addition, the information provided by this research may be used to design strategies to minimize RF exposure. © 2017 Elsevier Ltd

Published
2017

20. Germline rearrangements in families with strong family history of glioma and malignant melanoma, colon, and breast cancer

Author

Andersson, Ulrika, Wibom, Carl, Cederquist, Kristina, Aradottir, Steina, Borg, Åke, Armstrong, Georgina N., Shete, Sanjay, Lau, Ching C., Bainbridge, Matthew N., Claus, Elizabeth B., Barnholtz-Sloan, Jill, Lai, Rose, Il'yasova, Dora, Houlston, Richard S., Schildkraut, Joellen, Bernstein, Jonine L., Olson, Sara H., Jenkins, Robert B., Lachance, Daniel H., Wrensch, Margaret, Davis, Faith G., Merrell, Ryan, Johansen, Christoffer, Sadetzki, Siegal, Bondy, Melissa L., Melin, Beatrice S., Adatto, Phyllis, Morice, Fabian, Payen, Sam, McQuinn, Lacey, McGaha, Rebecca, Guerra, Sandra, Paith, Leslie, Roth, Katherine, Zeng, Dong, Zhang, Hui, Yung, Alfred, Aldape, Kenneth, Gilbert, Mark, Weinberger, Jeffrey, Colman, Howard, Conrad, Charles, de Groot, John, Forman, Arthur, Groves, Morris, Levin, Victor, Loghin, Monica, Puduvalli, Vinay, Sawaya, Raymond, Heimberger, Amy, Lang, Frederick, Levine, Nicholas, Tolentino, Lori, Saunders, Kate, Thach, Thu-Trang, Iacono, Donna Dello, Sloan, Andrew, Gerson, Stanton, Selman, Warren, Bambakidis, Nicholas, Hart, David, Miller, Jonathan, Hoffer, Alan, Cohen, Mark, Rogers, Lisa, Nock, Charles J, Wolinsky, Yingli, Devine, Karen, Fulop, Jordonna, Barrett, Wendi, Shimmel, Kristen, Ostrom, Quinn, Barnett, Gene, Rosenfeld, Steven, Vogelbaum, Michael, Weil, Robert, Ahluwalia, Manmeet, Peereboom, David, Staugaitis, Susan, Schilero, Cathy, Brewer, Cathy, Smolenski, Kathy, McGraw, Mary, Naska, Theresa, Ram, Zvi, Blumenthal, Deborah T., Bokstein, Felix, Umansky, Felix, Zaaroor, Menashe, Cohen, Avi, Tzuk-Shina, Tzeela, Voldby, Bo, Laursen, René, Andersen, Claus, Brennum, Jannick, Henriksen, Matilde Bille, Marzouk, Maya, Davis, Mary Elizabeth, Boland, Eamon, Smith, Marcel, Eze, Ogechukwu, Way, Mahalia, Lada, Pat, Miedzianowski, Nancy, Frechette, Michelle, Paleologos, Nina, Byström, Gudrun, Svedberg, Eva, Huggert, Sara, Kimdal, Mikael, Sandström, Monica, Brännström, Nikolina, Hayat, Amina, Tihan, Tarik, Zheng, Shichun, Berger, Mitchel, Butowski, Nicholas, Chang, Susan, Clarke, Jennifer, Prados, Michael, Rice, Terri, Sison, Jeannette, Kivett, Valerie, Duo, Xiaoqin, Hansen, Helen, Hsuang, George, Lamela, Rosito, Ramos, Christian, Patoka, Joe, Wagenman, Katherine, Zhou, Mi, Klein, Adam, McGee, Nora, Pfefferle, Jon, Wilson, Callie, Morris, Pagan, Hughes, Mary, Britt-Williams, Marlin, Foft, Jessica, Madsen, Julia, Polony, Csaba, McCarthy, Bridget, Zahora, Candice, Villano, John, Engelhard, Herbert, Borg, Ake, Chanock, Stephen K, Collins, Peter, Elston, Robert, Kleihues, Paul, Kruchko, Carol, Petersen, Gloria, Plon, Sharon, Thompson, Patricia, Johansen, C., Sadetzki, S., Melin, B., Scheurer, Michael E., Liu, Yanhong, Yu, Robert K., Aldape, Kenneth D., Gilbert, Mark R., Weinberg, Jeffrey, Hosking, Fay J., Robertson, Lindsay, Papaemmanuil, Elli, Sloan, Andrew E., McKean-Cowdin, Roberta, Yechezkel, Galit Hirsh, Bruchim, Revital Bar-Sade, Aslanov, Lili, Kosteljanetz, Michael, Broholm, Helle, Schubert, Erica, DeAngelis, Lisa, Yang, Ping, Rynearson, Amanda, Henriksson, Roger, Lada, Patricia, Wiencke, John, Wiemels, Joe, McCoy, Lucie, and McCarthy, Bridget J.

Subjects
Male, Cancer Research, Neurologi, Colorectal cancer, Bioinformatics, Germline, 0302 clinical medicine, glioma, Medicine, TP53, Family history, Melanoma, family history, 0303 health sciences, Brain Neoplasms, MLH1, Nuclear Proteins, CDKN2A/B, Middle Aged, Pedigree, 3. Good health, MutS Homolog 2 Protein, Neurology, Oncology, Child, Preschool, 030220 oncology & carcinogenesis, Basic and Translational Investigations, Colonic Neoplasms, Female, MutL Protein Homolog 1, Adult, Breast Neoplasms, Young Adult, 03 medical and health sciences, Germline mutation, Breast cancer, Glioma, Humans, Genetic Predisposition to Disease, neoplasms, Cyclin-Dependent Kinase Inhibitor p16, Germ-Line Mutation, Adaptor Proteins, Signal Transducing, Cyclin-Dependent Kinase Inhibitor p15, 030304 developmental biology, Cancer och onkologi, business.industry, Cancer, medicine.disease, MSH2, nervous system diseases, Checkpoint Kinase 2, Cancer and Oncology, Cancer research, Neurology (clinical), Tumor Suppressor Protein p53, business
Abstract

Background: Although familial susceptibility to glioma is known, the genetic basis for this susceptibility remains unidentified in the majority of glioma-specific families. An alternative approach to identifying such genes is to examine cancer pedigrees, which include glioma as one of several cancer phenotypes, to determine whether common chromosomal modifications might account for the familial aggregation of glioma and other cancers. Methods: Germline rearrangements in 146 glioma families (from the Gliogene Consortium; http://www.gliogene.org/) were examined using multiplex ligation-dependent probe amplification. These families all had at least 2 verified glioma cases and a third reported or verified glioma case in the same family or 2 glioma cases in the family with at least one family member affected with melanoma, colon, or breast cancer. The genomic areas covering TP53, CDKN2A, MLH1, and MSH2 were selected because these genes have been previously reported to be associated with cancer pedigrees known to include glioma. Results: We detected a single structural rearrangement, a deletion of exons 1-6 in MSH2, in the proband of one family with 3 cases with glioma and one relative with colon cancer. Conclusions: Large deletions and duplications are rare events in familial glioma cases, even in families with a strong family history of cancers that may be involved in known cancer syndromes. Meeting Abstract: P04.02 published in the same journal, Vol. 16, Suppl. 2.

Published
2014

21. Ovarian cancer and smoking: individual participant meta-analysis including 28,114 women with ovarian cancer from 51 epidemiological studies

Author

Gaitskell, K, Hermon, C, Moser, K, Reeves, G, Peto, R, Brinton, L, Marchbanks, P, Negri, E, Ness, R, Peeters, PHM, Vessey, M, Calle, EE, Gapstur, SM, Patel, AV, Dal Maso, L, Talamini, R, Chetrit, A, Hirsh-Yechezkel, G, Lubin, F, Sadetzki, S, Banks, E, Beral, V, Bull, D, Callaghan, K, Crossley, B, Goodill, A, Green, J, Key, T, Sitas, F, Collins, R, Doll, R, Gonzalez, A, Lee, N, Ory, HW, Peterson, HB, Wingo, PA, Martin, N, Pardthaisong, T, Silpisornkosol, S, Theetranont, C, Boosiri, B, Chutivongse, S, Jimakorn, P, Virutamasen, P, Wongsrichanalai, C, Tjonneland, A, Titus-Ernstoff, L, Byers, T, Rohan, T, Mosgaard, BJ, Yeates, D, Freudenheim, JL, Chang-Claude, J, Kaaks, R, Anderson, KE, Folsom, A, Robien, K, Hampton, J, Newcomb, PA, Rossing, MA, Thomas, DB, Weiss, NS, Riboli, E, Clavel-Chapelon, F, Cramer, D, Hankinson, SE, Tworoger, SS, Franceschi, S, La Vecchia, C, Adami, HO, Magnusson, C, Riman, T, Weiderpass, Elisabete, Wolk, A, Schouten, LJ, van den Brandt, PA, Chantarakul, N, Koetsawang, S, Rachawat, D, Palli, D, Black, A, Brinton, LA, Freedman, DM, Hartge, P, Hsing, AW, Lacey, JV, Hoover, RN, Schairer, C, Urban, M, Graff-Iversen, Sidsel, Selmer, Randi, Bain, CJ, Green, AC, Purdie, DM, Siskind, V, Webb, PM, Moysich, K, McCann, SE, Hannaford, P, Kay, C, Binns, CW, Lee, AH, Zhang, M, Ness, RB, Nasca, P, Coogan, PF, Palmer, JR, Rosenberg, L, Kelsey, J, Paffenbarger, R, Whittemore, A, Katsouyanni, K, Trichopoulou, A, Trichopoulos, D, Tzonou, A, Dabancens, A, Martinez, L, Molina, R, Salas, O, Goodman, MT, Lurie, G, Carney, ME, Wilkens, LR, Hartman, L, Manjer, J, Olsson, H, Grisso, JA, Morgan, M, Wheeler, JE, Bunker, CH, Edwards, RP, Modugno, F, Casagrande, J, Pike, MC, Ross, RK, Wu, AH, Miller, AB, Kumle, Merethe, Gram, Inger Torhild, Lund, Eiliv, McGowan, L, Shu, XO, Zheng, W, Farley, TMM, Holck, S, Meirik, O, Risch, HA, E. E. Calle, S. M. Gapstur, A. V. Patel, L. Dal Maso, R. Talamini, A. Chetrit, G. Hirsh Yechezkel, F. Lubin, S. Sadetzki, E. Bank, V. Beral, D. Bull, K. Callaghan, B. Crossley, K. Gaitskell, A. Goodill, J. Green, C. Hermon, T. Key, K. Moser, G. Reeve, F. Sita, R. Collin, R. Doll, R. Peto, C. A. Gonzalez, N. Lee, P. Marchbank, H. W. Ory, H. B. Peterson, P. A. Wingo, N. Martin, T. Pardthaisong, S. Silpisornkosol, C. Theetranont, B. Boosiri, S. Chutivongse, P. Jimakorn, P. Virutamasen, C. Wongsrichanalai, A. Tjonneland, L. Titus Ernstoff, T. Byer, T. Rohan, B. J. Mosgaard, M. Vessey, D. Yeate, J. L. Freudenheim, J. Chang Claude, R. Kaak, K. E. Anderson, A. Folsom, K. Robien, J. Hampton, P. A. Newcomb, M. A. Rossing, D. B. Thoma, N. S. Wei, E. Riboli, F. Clavel Chapelon, D. Cramer, S. E. Hankinson, S. S. Tworoger, S. Franceschi, C. La Vecchia, E. Negri, H. O. Adami, C. Magnusson, T. Riman, E. Weiderpa, A. Wolk, L. J. Schouten, P. A. van den Brandt, N. Chantarakul, S. Koetsawang, D. Rachawat, D. Palli, A. Black, L. A. Brinton, D. M. Freedman, P. Hartge, A. W. Hsing, J. Lacey, R. N. Hoover, C. Schairer, M. Urban, S. Graff Iversen, R. Selmer, C. J. Bain, A. C. Green, D. M. Purdie, V. Siskind, P. M. Webb, K. Moysich, S. E. Mccann, P. Hannaford, C. Kay, C. W. Binn, A. H. Lee, M. Zhang, R. B. Ne, P. Nasca, P. F. Coogan, J. R. Palmer, L. Rosenberg, J. Kelsey, R. Paffenbarger, A. Whittemore, K. Katsouyanni, A. Trichopoulou, D. Trichopoulo, A. Tzonou, A. Dabancen, L. Martinez, R. Molina, O. Sala, M. T. Goodman, G. Lurie, M. E. Carney, L. R. Wilken, L. Hartman, J. Manjer, H. Olsson, J. A. Grisso, M. Morgan, J. E. Wheeler, C. H. Bunker, R. P. Edward, F. Modugno, P. H. M. Peeter, J. Casagrande, M. C. Pike, R. K. Ro, A. H. Wu, A. B. Miller, M. Kumle, I. T. Gram, E. Lund, L. Mcgowan, X. O. Shu, W. Zheng, T. M. M. Farley, S. Holck, O. Meirik, H. A. Risch, Epidemiologie, RS: CAPHRI School for Public Health and Primary Care, and RS: GROW - School for Oncology and Reproduction

Subjects
hormonal factor, Oncology, body-mass index, Comorbidity, anthropometric measurement, Body Mass Index, 0302 clinical medicine, Epidemiology, Cancer Type - Ovarian Cancer, 030212 general & internal medicine, epithelial ovarian, Prospective cohort study, oral contraceptives, Ovarian Neoplasms, Incidence (epidemiology), Incidence, Smoking, Articles, Middle Aged, Adenocarcinoma, Mucinous, 3. Good health, Causality, Europe, risk-factor, Serous fluid, 030220 oncology & carcinogenesis, Meta-analysis, Adenocarcinoma, Female, Risk, Adult, medicine.medical_specialty, prospective cohort, Etiology - Exogenous Factors in the Origin and Cause of Cancer, Risk Assessment, methods, 03 medical and health sciences, Internal medicine, oral-contraceptive use, medicine, cancer, Humans, Women, tobacco smoking, therapy, cigarette-smoking, VDP::Medical disciplines: 700::Clinical medical disciplines: 750::Oncology: 762, business.industry, Research, medicine.disease, VDP::Medisinske Fag: 700::Klinisk medisinske fag: 750::Onkologi: 762, Relative risk, North America, Other, United-State, business, Ovarian cancer, Meta-Analysis
Abstract

BACKGROUND: Smoking has been linked to mucinous ovarian cancer, but its effects on other ovarian cancer subtypes and on overall ovarian cancer risk are unclear, and the findings from most studies with relevant data are unpublished. To assess these associations, we review the published and unpublished evidence. METHODS: Eligible epidemiological studies were identified by electronic searches, review articles, and discussions with colleagues. Individual participant data for 28,114 women with and 94,942 without ovarian cancer from 51 epidemiological studies were analysed centrally, yielding adjusted relative risks (RRs) of ovarian cancer in smokers compared with never smokers. FINDINGS: After exclusion of studies with hospital controls, in which smoking could have affected recruitment, overall ovarian cancer incidence was only slightly increased in current smokers compared with women who had never smoked (RR 1·06, 95% CI 1·01-1·11, p=0·01). Of 17,641 epithelial cancers with specified histology, 2314 (13%) were mucinous, 2360 (13%) endometrioid, 969 (5%) clear-cell, and 9086 (52%) serous. Smoking-related risks varied substantially across these subtypes (p(heterogeneity)

Published
2016

22. Menopausal hormone use and ovarian cancer risk : individual participant meta-analysis of 52 epidemiological studies

Author

Gapstur, S. M., Patel, A. V., Banks, E., Dal Maso, L., Talamini, R., Chetrit, A., Hirsh-Yechezkel, G., Lubin, F., Sadetzki, S., Beral, V., Bull, D., Cairns, B., Crossley, B., Gaitskell, K., Goodill, A., Green, J., Hermon, C., Key, T., Moser, K., Reeves, G., Sitas, F., Collins, R., Peto, R., Gonzalez, C. A., Lee, N., Marchbanks, P., Ory, H. W., Peterson, H. B., Wingo, P. A., Martin, N., Silpisornkosol, S., Theetranont, C., Boosiri, B., Chutivongse, S., Jimakorn, P., Virutamasen, P., Wongsrichanalai, C., Goodman, M. T., Lidegaard, O., Kjaer, S. K., Morch, L. S., Tjonneland, A., Byers, T., Rohan, T., Mosgaard, B., Vessey, M., Yeates, D., Onland-Moret, N. C., Peeters, P. H. M., and Collaborative Grp Epidemiological

Subjects
WOMEN, HEALTH, THERAPY
Abstract

Background Half the epidemiological studies with information about menopausal hormone therapy and ovarian cancer risk remain unpublished, and some retrospective studies could have been biased by selective participation or recall. We aimed to assess with minimal bias the effects of hormone therapy on ovarian cancer risk. Methods Individual participant datasets from 52 epidemiological studies were analysed centrally. The principal analyses involved the prospective studies (with last hormone therapy use extrapolated forwards for up to 4 years). Sensitivity analyses included the retrospective studies. Adjusted Poisson regressions yielded relative risks (RRs) versus never-use. Findings During prospective follow-up, 12 110 postmenopausal women, 55% (6601) of whom had used hormone therapy, developed ovarian cancer. Among women last recorded as current users, risk was increased even with Interpretation The increased risk may well be largely or wholly causal; if it is, women who use hormone therapy for 5 years from around age 50 years have about one extra ovarian cancer per 1000 users and, if its prognosis is typical, about one extra ovarian cancer death per 1700 users.

Published
2015

23. Menopausal hormone use and ovarian cancer risk: individual participant meta-analysis of 52 epidemiological studies

Author

Gapstur, S. M. Patel, A. V. Banks, E. Dal Maso, L. and Talamini, R. Chetrit, A. Hirsh-Yechezkel, G. Lubin, F. and Sadetzki, S. Beral, V. Bull, D. Cairns, B. Crossley, B. and Gaitskell, K. Goodill, A. Green, J. Hermon, C. Key, T. Moser, K. Reeves, G. Sitas, F. Collins, R. Peto, R. Gonzalez, C. A. Lee, N. Marchbanks, P. Ory, H. W. and Peterson, H. B. Wingo, P. A. Martin, N. Silpisornkosol, S. and Theetranont, C. Boosiri, B. Chutivongse, S. Jimakorn, P. and Virutamasen, P. Wongsrichanalai, C. Goodman, M. T. and Lidegaard, O. Kjaer, S. K. Morch, L. S. Tjonneland, A. and Byers, T. Rohan, T. Mosgaard, B. Vessey, M. Yeates, D. and Freudenheim, J. L. Titus, L. J. Chang-Claude, J. Kaaks, R. Anderson, K. E. Lazovich, D. Robien, K. Hampton, J. and Newcomb, P. A. Rossing, M. A. Thomas, D. B. Weiss, N. S. and Lokkegaard, E. Riboli, E. Clavel-Chapelon, F. Cramer, D. and Hankinson, S. E. Tamimi, R. M. Tworoger, S. S. and Franceschi, S. La Vecchia, C. Negri, E. Adami, H. O. and Magnusson, C. Riman, T. Weiderpass, E. Wolk, A. and Schouten, L. J. van den Brandt, P. A. Chantarakul, N. and Koetsawang, S. Rachawat, D. Palli, D. Black, A. Brinton, L. A. Freedman, D. M. Hartge, P. Hsing, A. W. Jnr, J. V. Lacey Lissowska, J. Hoover, R. N. Schairer, C. Babb, C. and Urban, M. Graff-Iversen, S. Selmer, R. Bain, C. J. and Green, A. C. Purdie, D. M. Siskind, V. Webb, P. M. and Moysich, K. McCann, S. E. Hannaford, P. Kay, C. Binns, C. W. Lee, A. H. Zhang, M. Ness, R. B. Nasca, P. and Coogan, P. F. Palmer, J. R. Rosenberg, L. Whittemore, A. and Katsouyanni, K. Trichopoulou, A. Trichopoulos, D. Tzonou, A. and Dabancens, A. Martinez, L. Molina, R. Salas, O. and Lurie, G. Carney, M. E. Wilkens, L. R. Hartman, L. and Manjer, J. Olsson, H. Kumle, M. Grisso, J. A. Morgan, M. and Wheeler, J. E. Edwards, R. P. Kelley, J. L. Modugno, F. and Onland-Moret, N. C. Peeters, P. H. M. Casagrande, J. and Pike, M. C. Wu, A. H. Canfell, K. Miller, A. B. Gram, I. T. Lund, E. McGowan, L. Shu, X. O. Zheng, W. Farley, T. M. M. Holck, S. Meirik, O. Risch, H. A. Collaborative Grp Epidemiological

Abstract

Background Half the epidemiological studies with information about menopausal hormone therapy and ovarian cancer risk remain unpublished, and some retrospective studies could have been biased by selective participation or recall. We aimed to assess with minimal bias the effects of hormone therapy on ovarian cancer risk. Methods Individual participant datasets from 52 epidemiological studies were analysed centrally. The principal analyses involved the prospective studies (with last hormone therapy use extrapolated forwards for up to 4 years). Sensitivity analyses included the retrospective studies. Adjusted Poisson regressions yielded relative risks (RRs) versus never-use. Findings During prospective follow-up, 12 110 postmenopausal women, 55% (6601) of whom had used hormone therapy, developed ovarian cancer. Among women last recorded as current users, risk was increased even with

Published
2015

25. The MOBI-Kids study protocol: Challenges in assessing childhood and adolescent exposure to electromagnetic fields from wireless telecommunication technologies and possible association with brain tumor risk

Author

Sadetzki, S. Langer, C.E. Bruchim, R. Kundi, M. Merletti, F. Vermeulen, R. Kromhout, H. Ae-Kyoung, L. Maslanyj, M. Sim, M.R. Taki, M. Wiart, J. Armstrong, B. Milne, E. Benke, G. Schattner, R. Hutter, H.-P. Woehrer, A. Krewski, D. Mohipp, C. Momoli, F. Ritvo, P. Spinelli, J. Lacour, B. Delmas, D. Remen, T. Radon, K. Weinmann, T. Klostermann, S. Heinrich, S. Petridou, E. Bouka, E. Panagopoulou, P. Dikshit, R. Nagrani, R. Even-Nir, H. Chetrit, A. Maule, M. Migliore, E. Filippini, G. Miligi, L. Mattioli, S. Yamaguchi, N. Kojimahara, N. Ha, M. Choi, K.-H. Mannetje, A. Eng, A. Woodward, A. Carretero, G. Alguacil, J. Aragones, N. Suare-Varela, M.M. Goedhart, G. Schouten-van Meeteren, A.A.Y.N. Reedijk, A.A.M.J. Cardis, E.

Abstract

The rapid increase in mobile phone use in young people has generated concern about pos- sible health effects of exposure to radiofrequency (RF) and extremely low frequency (ELF) electromagnetic fields (EMF). MOBI-Kids, a multinational case-control study, investigates the potential effects of childhood and adolescent exposure to EMF from mobile communi- cations technologies on brain tumor risk in 14 countries. The study, which aims to include approximately 1,000 brain tumor cases aged 10-24 years and two individually matched controls for each case, follows a common protocol and builds upon the methodological experience of the INTERPHONE study. The design and conduct of a study on EMF expo- sure and brain tumor risk in young people in a large number of countries is complex and poses methodological challenges.This manuscript discusses the design of MOBI-Kids and describes the challenges and approaches chosen to address them, including: (1) the choice of controls operated for suspected appendicitis, to reduce potential selection bias related to lowresponse rates among population controls; (2) investigating a young study population spanning a relatively wide age range; (3) conducting a large, multinational epidemiologi- cal study, while adhering to increasingly stricter ethics requirements; (4) investigating a rare and potentially fatal disease; and (5) assessing exposure to EMF from communication technologies. Our experience in thus far developing and implementing the study protocol indicates that MOBI-Kids is feasible and will generate results that will contribute to the understanding of potential brain tumor risks associated with use of mobile phones and other wireless communications technologies among young people. © 2014.

Published
2014

27. Germline Mutation in BRCA1 or BRCA2 and Ten-Year Survival for Women Diagnosed with Epithelial Ovarian Cancer

Author

Candido-dos-Reis, FJ, Song, H, Goode, EL, Cunningham, JM, Fridley, BL, Larson, MC, Alsop, K, Dicks, E, Harrington, P, Ramus, SJ, de Fazio, A, Mitchell, G, Fereday, S, Bolton, KL, Gourley, C, Michie, C, Karlan, B, Lester, J, Walsh, C, Cass, I, Olsson, H, Gore, M, Benitez, JJ, Garcia, MJ, Andrulis, I, Mulligan, AM, Glendon, G, Blanco, I, Lazaro, C, Whittemore, AS, McGuire, V, Sieh, W, Montagna, M, Alducci, E, Sadetzki, S, Chetrit, A, Kwong, A, Kjaer, SK, Jensen, A, Hogdall, E, Neuhausen, S, Nussbaum, R, Daly, M, Greene, MH, Mai, PL, Loud, JT, Moysich, K, Toland, AE, Lambrechts, D, Ellis, S, Frost, D, Brenton, JD, Tischkowitz, M, Easton, DF, Antoniou, A, Chenevix-Trench, G, Gayther, SA, Bowtell, D, Pharoah, PDP, Candido-dos-Reis, FJ, Song, H, Goode, EL, Cunningham, JM, Fridley, BL, Larson, MC, Alsop, K, Dicks, E, Harrington, P, Ramus, SJ, de Fazio, A, Mitchell, G, Fereday, S, Bolton, KL, Gourley, C, Michie, C, Karlan, B, Lester, J, Walsh, C, Cass, I, Olsson, H, Gore, M, Benitez, JJ, Garcia, MJ, Andrulis, I, Mulligan, AM, Glendon, G, Blanco, I, Lazaro, C, Whittemore, AS, McGuire, V, Sieh, W, Montagna, M, Alducci, E, Sadetzki, S, Chetrit, A, Kwong, A, Kjaer, SK, Jensen, A, Hogdall, E, Neuhausen, S, Nussbaum, R, Daly, M, Greene, MH, Mai, PL, Loud, JT, Moysich, K, Toland, AE, Lambrechts, D, Ellis, S, Frost, D, Brenton, JD, Tischkowitz, M, Easton, DF, Antoniou, A, Chenevix-Trench, G, Gayther, SA, Bowtell, D, and Pharoah, PDP

Abstract

PURPOSE: To analyze the effect of germline mutations in BRCA1 and BRCA2 on mortality in patients with ovarian cancer up to 10 years after diagnosis. EXPERIMENTAL DESIGN: We used unpublished survival time data for 2,242 patients from two case-control studies and extended survival time data for 4,314 patients from previously reported studies. All participants had been screened for deleterious germline mutations in BRCA1 and BRCA2. Survival time was analyzed for the combined data using Cox proportional hazard models with BRCA1 and BRCA2 as time-varying covariates. Competing risks were analyzed using Fine and Gray model. RESULTS: The combined 10-year overall survival rate was 30% [95% confidence interval (CI), 28%-31%] for non-carriers, 25% (95% CI, 22%-28%) for BRCA1 carriers, and 35% (95% CI, 30%-41%) for BRCA2 carriers. The HR for BRCA1 was 0.53 at time zero and increased over time becoming greater than one at 4.8 years. For BRCA2, the HR was 0.42 at time zero and increased over time (predicted to become greater than 1 at 10.5 years). The results were similar when restricted to 3,202 patients with high-grade serous tumors and to ovarian cancer-specific mortality. CONCLUSIONS: BRCA1/2 mutations are associated with better short-term survival, but this advantage decreases over time and in BRCA1 carriers is eventually reversed. This may have important implications for therapy of both primary and relapsed disease and for analysis of long-term survival in clinical trials of new agents, particularly those that are effective in BRCA1/2 mutation carriers.

Published
2015

28. Menopausal hormone use and ovarian cancer risk: individual participant meta-analysis of 52 epidemiological studies

Author

Epi Kanker Team 1, JC onderzoeksprogramma Kanker, Cancer, Cardiovasculaire Epi Team 3, Circulatory Health, JC onderzoeksprogramma Cardiovasculaire Epidemiologie, Gapstur, S. M., Patel, A. V., Banks, E., Dal Maso, L., Talamini, R., Chetrit, A., Hirsh-Yechezkel, G., Lubin, F., Sadetzki, S., Beral, V., Bull, D., Cairns, B., Crossley, B., Gaitskell, K., Goodill, A., Green, J., Hermon, C., Key, T., Moser, K., Reeves, G., Sitas, F., Collins, R., Peto, R., Gonzalez, C. A., Lee, N., Marchbanks, P., Ory, H. W., Peterson, H. B., Wingo, P. A., Martin, N., Silpisornkosol, S., Theetranont, C., Boosiri, B., Chutivongse, S., Jimakorn, P., Virutamasen, P., Wongsrichanalai, C., Goodman, M. T., Lidegaard, O., Kjaer, S. K., Morch, L. S., Tjonneland, A., Byers, T., Rohan, T., Mosgaard, B., Vessey, M., Yeates, D., Onland-Moret, N. C., Peeters, P. H. M., Collaborative Grp Epidemiological, Epi Kanker Team 1, JC onderzoeksprogramma Kanker, Cancer, Cardiovasculaire Epi Team 3, Circulatory Health, JC onderzoeksprogramma Cardiovasculaire Epidemiologie, Gapstur, S. M., Patel, A. V., Banks, E., Dal Maso, L., Talamini, R., Chetrit, A., Hirsh-Yechezkel, G., Lubin, F., Sadetzki, S., Beral, V., Bull, D., Cairns, B., Crossley, B., Gaitskell, K., Goodill, A., Green, J., Hermon, C., Key, T., Moser, K., Reeves, G., Sitas, F., Collins, R., Peto, R., Gonzalez, C. A., Lee, N., Marchbanks, P., Ory, H. W., Peterson, H. B., Wingo, P. A., Martin, N., Silpisornkosol, S., Theetranont, C., Boosiri, B., Chutivongse, S., Jimakorn, P., Virutamasen, P., Wongsrichanalai, C., Goodman, M. T., Lidegaard, O., Kjaer, S. K., Morch, L. S., Tjonneland, A., Byers, T., Rohan, T., Mosgaard, B., Vessey, M., Yeates, D., Onland-Moret, N. C., Peeters, P. H. M., and Collaborative Grp Epidemiological

Published
2015

29. Ovarian cancer and smoking: individual participant meta-analysis including 28 114 women with ovarian cancer from 51 epidemiological studies

Author

Beral, V. Gaitskell, K. Hermon, C. Moser, K. Reeves, G. and Peto, R. Brinton, L. Marchbanks, P. Negri, E. Ness, R. Peeters, P. H. M. Vessey, M. Calle, E. E. Gapstur, S. M. Patel, A. V. Dal Maso, L. Talamini, R. Chetrit, A. and Hirsh-Yechezkel, G. Lubin, F. Sadetzki, S. Banks, E. and Bull, D. Callaghan, K. Crossley, B. Goodill, A. Green, J. Key, T. Sitas, F. Collins, R. Doll, R. Gonzalez, A. Lee, N. Ory, H. W. Peterson, H. B. Wingo, P. A. and Martin, N. Pardthaisong, T. Silpisornkosol, S. Theetranont, C. Boosiri, B. Chutivongse, S. Jimakorn, P. Virutamasen, P. Wongsrichanalai, C. Tjonneland, A. Titus-Ernstoff, L. and Byers, T. Rohan, T. Mosgaard, B. J. Yeates, D. and Freudenheim, J. L. Chang-Claude, J. Kaaks, R. Anderson, K. E. Folsom, A. Robien, K. Hampton, J. Newcomb, P. A. and Rossing, M. A. Thomas, D. B. Weiss, N. S. Riboli, E. and Clavel-Chapelon, F. Cramer, D. Hankinson, S. E. Tworoger, S. S. Franceschi, S. La Vecchia, C. Adami, H. O. Magnusson, C. Riman, T. Weiderpass, E. Wolk, A. Schouten, L. J. and van den Brandt, P. A. Chantarakul, N. Koetsawang, S. and Rachawat, D. Palli, D. Black, A. Freedman, D. M. Hartge, P. Hsing, A. W. Lacey, Jr., J. V. Hoover, R. N. and Schairer, C. Urban, M. Graff-Iversen, S. Selmer, R. and Bain, C. J. Green, A. C. Purdie, D. M. Siskind, V. Webb, P. M. Moysich, K. McCann, S. E. Hannaford, P. Kay, C. and Binns, C. W. Lee, A. H. Zhang, M. Nasca, P. Coogan, P. F. Palmer, J. R. Rosenberg, L. Kelsey, J. and Paffenbarger, R. Whittemore, A. Katsouyanni, K. and Trichopoulou, A. Trichopoulos, D. Tzonou, A. Dabancens, A. and Martinez, L. Molina, R. Salas, O. Goodman, M. T. and Lurie, G. Carney, M. E. Wilkens, L. R. Hartman, L. and Manjer, J. Olsson, H. Grisso, J. A. Morgan, M. Wheeler, J. E. Bunker, C. H. Edwards, R. P. Modugno, F. and Casagrande, J. Pike, M. C. Ross, R. K. Wu, A. H. Miller, A. B. Kumle, M. Gram, I. T. Lund, E. McGowan, L. and Shu, X. O. Zheng, W. Farley, T. M. M. Holck, S. Meirik, O. Risch, H. A. Collaborative Grp Epidemiological Natl Israeli Study Ovarian Canc Nurses Hlth Study

Abstract

Background Smoking has been linked to mucinous ovarian cancer, but its effects on other ovarian cancer subtypes and on overall ovarian cancer risk are unclear, and the findings from most studies with relevant data are unpublished. To assess these associations, we review the published and unpublished evidence. Methods Eligible epidemiological studies were identified by electronic searches, review articles, and discussions with colleagues. Individual participant data for 28 114 women with and 94 942 without ovarian cancer from 51 epidemiological studies were analysed centrally, yielding adjusted relative risks (RRs) of ovarian cancer in smokers compared with never smokers. Findings After exclusion of studies with hospital controls, in which smoking could have affected recruitment, overall ovarian cancer incidence was only slightly increased in current smokers compared with women who had never smoked (RR 1.06, 95% CI 1.01-1.11, p=0.01). Of 17 641 epithelial cancers with specified histology, 2314 (13%) were mucinous, 2360 (13%) endometrioid, 969 (5%) clear-cell, and 9086 (52%) serous. Smoking-related risks varied substantially across these subtypes (p(heterogeneity)

Published
2012

30. Association between BRCA1 and BRCA2 Mutations and Survival in Women with Invasive Epithelial Ovarian Cancer

Author

Fridley, BL, Goode, EL, Høgdall, E, Jensen, A, Cass, I, Kjær, SK, Johnatty, SE, Nicoletto, MO, D'Andrea, E, Montagna, M, Blanco, I, Lázaro, C, Ma, ESK, Daly, MB, Godwin, AK, Eeles, R, Evans, DG, Frost, D, Peock, S, Hartge, P, Gail, MH, Neuhausen, S, García, MJ, Benítez, J, Sinilnikova, O, Easton, DF, Healey, S, McGuffog, L, Barrowdale, D, Despierre, E, Lambrechts, D, Karlan, BY, Ramus, SJ, Sadetzki, S, Goh, C, ChenevixTrench, G, Bolton, KL, Li, AJ, Walsh, C, Gross, J, Steele, L, Beattie, MS, Chan, S, Nussbaum, RL, Moysich, KB, Leuchter, R, Borg, Å, Olsson, H, Kristoffersson, U, Sieh, W, McGuire, V, Whittemore, AS, Tyrer, J, Song, H, Michie, CO, Gourley, C, Gore, ME, Senter, L, Toland, AE, Glendon, G, HirshYechezkel, G, Lubin, F, Chetrit, A, Mai, PL, Greene, MH, Loud, JT, Levine, DA, Gordon, O, GarciaClosas, M, Gayther, SA, Chanock, SJ, Antoniou, AC, Pharoah, PDP, Andrulis, IL, and Kwong, A

Subjects
endocrine system diseases, skin and connective tissue diseases, female genital diseases and pregnancy complications
Abstract

Context: Approximately 10% of women with invasive epithelial ovarian cancer (EOC) carry deleterious germline mutations in BRCA1 or BRCA2. A recent article suggested that BRCA2-related EOC was associated with an improved prognosis, but the effect of BRCA1 remains unclear. Objective: To characterize the survival of BRCA carriers with EOC compared with noncarriers and to determine whether BRCA1 and BRCA2 carriers show similar survival patterns. Design, Setting, and Participants: A pooled analysis of 26 observational studies on the survival of women with ovarian cancer, which included data from 1213 EOC cases with pathogenic germline mutations in BRCA1 (n=909) or BRCA2 (n=304) and from 2666 noncarriers recruited and followed up at variable times between 1987 and 2010 (the median year of diagnosis was 1998). Main Outcome Measure: Five-year overall mortality. Results: The 5-year overall survival was 36% (95% CI, 34%-38%) for noncarriers, 44% (95% CI, 40%-48%) for BRCA1 carriers, and 52% (95% CI, 46%-58%) for BRCA2 carriers. After adjusting for study and year of diagnosis, BRCA1 and BRCA2 mutation carriers showed amore favorable survival than noncarriers (for BRCA1: hazard ratio [HR], 0.78; 95% CI, 0.68-0.89; P, link_to_OA_fulltext

Published
2012

31. Ovarian Cancer and Body Size: Individual Participant Meta-Analysis Including 25,157 Women with Ovarian Cancer from 47 Epidemiological Studies

Author

Beral, V. Hermon, C. Peto, R. Reeves, G. Brinton, L. and Marchbanks, P. Negri, E. Ness, R. Peeters, P. H. M. and Vessey, M. Calle, E. E. Gapstur, S. M. Patel, A. V. Dal Maso, L. Talamini, R. Chetrit, A. Hirsh-Yechezkel, G. and Lubin, F. Sadetzki, S. Allen, N. Bull, D. Callaghan, K. and Crossley, B. Gaitskell, K. Goodill, A. Green, J. and Key, T. Moser, K. Collins, R. Doll, R. Gonzalez, C. A. and Lee, N. Ory, H. W. Peterson, H. B. Wingo, P. A. and Martin, N. Pardthaisong, T. Silpisornkosol, S. Theetranont, C. Boosiri, B. Chutivongse, S. Jimakorn, P. Virutamasen, P. Wongsrichanalai, C. Tjonneland, A. Titus-Ernstoff, L. and Byers, T. Rohan, T. Mosgaard, B. J. Yeates, D. and Freudenheim, J. L. Chang-Claude, J. Kaaks, R. Anderson, K. E. Folsom, A. Robien, K. Rossing, M. A. Thomas, D. B. and Weiss, N. S. Riboli, E. Clavel-Chapelon, F. Cramer, D. and Hankinson, S. E. Tworoger, S. S. Franceschi, S. La Vecchia, C. Magnusson, C. Riman, T. Weiderpass, E. Wolk, A. Schouten, L. J. van den Brandt, P. A. Chantarakul, N. and Koetsawang, S. Rachawat, D. Palli, D. Black, A. de Gonzalez, A. Berrington Freedman, D. M. Hartge, P. Hsing, A. W. Lacey, Jr., J. V. Hoover, R. N. Schairer, C. and Graff-Iversen, S. Selmer, R. Bain, C. J. Green, A. C. and Purdie, D. M. Siskind, V. Webb, P. M. McCann, S. E. and Hannaford, P. Kay, C. Binns, C. W. Lee, A. H. Zhang, M. and Ness, R. B. Nasca, P. Coogan, P. F. Palmer, J. R. and Rosenberg, L. Kelsey, J. Paffenbarger, R. Whittemore, A. and Katsouyanni, K. Trichopoulou, A. Trichopoulos, D. Tzonou, A. and Dabancens, A. Martinez, L. Molina, R. Salas, O. and Goodman, M. T. Lurie, G. Carney, M. E. Wilkens, L. R. and Hartman, L. Manjer, J. Olsson, H. Grisso, J. A. Morgan, M. Wheeler, J. E. Casagrande, J. Pike, M. C. Ross, R. K. and Wu, A. H. Miller, A. B. Kumle, M. Lund, E. McGowan, L. Shu, X. O. Zheng, W. Farley, T. M. M. Holck, S. and Meirik, O. Risch, H. A. Collaborative Grp Epidemiol Studie

Abstract

Background: Only about half the studies that have collected information on the relevance of women’s height and body mass index to their risk of developing ovarian cancer have published their results, and findings are inconsistent. Here, we bring together the worldwide evidence, published and unpublished, and describe these relationships. Methods and Findings: Individual data on 25,157 women with ovarian cancer and 81,311 women without ovarian cancer from 47 epidemiological studies were collected, checked, and analysed centrally. Adjusted relative risks of ovarian cancer were calculated, by height and by body mass index. Ovarian cancer risk increased significantly with height and with body mass index, except in studies using hospital controls. For other study designs, the relative risk of ovarian cancer per 5 cm increase in height was 1.07 (95% confidence interval [CI], 1.05-1.09; p

Published
2012

32. Brain tumour risk in relation to mobile telephone use: results of the INTERPHONE international case-control study

Author

Cardis, E., Deltour, I., Vrijheid, M., Combalot, E., Moissonnier, M., Tardy, H., Armstrong, B., Giles, G., Brown, J., Siemiatycki, J., Parent, M. E., Nadon, L., Krewski, D., McBride, M. L., Johansen, C., Collatz, Christensen H., Auvinen, A., Kurttio, P., Lahkola, A., Salminen, T., Hours, M., Bernard, M., Montestruq, L., Schuez, J., Berg-Beckhoff, Gabriele, Schlehofer, B., Blettner, M., Sadetzki, S., Chetrit, A., Jarus-Hakak, A., Lagorio, S., Iavarone, I., Takebayashi, T., Yamaguchi, N., Woodward, A., Cook, A., Pearce, N., Tynes, T., Blaasaas, K. G., Klaeboe, L., Feychting, M., Loenn, S., Ahlbom, A., McKinney, P. A., Hepworth, S. J., Muir, K. R., Swerdlow, A. J., Schoemaker, M. J., Center for Research in Environmental Epidemiology (CREAL), and Universitat Pompeu Fabra [Barcelona] (UPF)-Catalunya ministerio de salud

Subjects
Adult, Male, Oncology, medicine.medical_specialty, Pathology, Relation (database), Epidemiology, Mobile telephone, Meningioma, 03 medical and health sciences, Electromagnetic Fields, 0302 clinical medicine, Glioma, Internal medicine, Odds Ratio, medicine, Humans, 030212 general & internal medicine, neoplasms, mobile phones, Brain Neoplasms, business.industry, Brain tumours, Case-control study, General Medicine, Middle Aged, medicine.disease, 3. Good health, nervous system diseases, Increased risk, Case-Control Studies, 030220 oncology & carcinogenesis, Cellular Phone, Medicine, Female, radiofrequency fields, business, Cell Phone
Abstract

International audience; Background: The rapid increase in mobile telephone use has generated concern about possible health risks related to radiofrequency electromagnetic fields from this technology. Methods: An interview-based case-control study with 2708 glioma and 2409 meningioma cases and matched controls was conducted in 13 countries using a common protocol. Results: A reduced odds ratio (OR) related to ever having been a regular mobile phone user was seen for glioma (OR 0.81, 95% confidence interval (CI): 0.70, 0.94) and meningioma (OR 0.79; 95% CI 0.68, 0.91), possibly reflecting participation bias or other methodological limitations. No elevated OR was observed 10 or more years after first phone use (glioma: OR 0.98, 95% CI 0.76, 1.26; meningioma: OR 0.83, 95% CI 0.61, 1.14). Odds ratios were below 1.0 for all deciles of lifetime number of phone calls and nine deciles of cumulative call time. In the tenth decile of recalled cumulative call time, 1640 hours or longer, the odds ratio was 1.40 (95% CI 1.03, 1.89) for glioma, and 1.15 (95% CI 0.81, 1.62) for meningioma; but there are implausible values of reported use in this group. Odds ratios for glioma tended to be greater in the temporal lobe than in other lobes of the brain, but the confidence intervals around the lobe-specific estimates were wide. Odds ratios for glioma tended to be greater in subjects who reported usual phone use on the same side of the head as their tumour than on the opposite side. Conclusions: Overall, no increase in risk of glioma or meningioma was observed with use of mobile phones. There were suggestions of an increased risk of glioma at the highest exposure levels, but biases and error prevent a causal interpretation. The possible effects of long-term heavy use of mobile phones require further investigation.

Published
2010

33. Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23 257 women with ovarian cancer and 87 303 controls

Author

Beral, V. Doll, R. Hermon, C. Peto, R. Reeves, G. and Brinton, L. Green, A. C. Marchbanks, P. Negri, E. Ness, R. Peeters, P. Vessey, M. Calle, E. E. Rodriguez, C. and Dal Maso, L. Talamini, R. Cramer, D. Hankinson, S. E. and Tworoger, S. S. Chetrit, A. Hirsh-Yechezkel, G. Lubin, F. and Sadetzki, S. Appleby, P. Banks, E. de Gonzalez, A. Berrington Bull, D. Crossley, B. Goodil, A. Green, I. and Green, J. Key, T. Collins, R. Gonzalez, C. A. Lee, N. Ory, H. W. Peterson, H. B. Wingo, P. A. Martin, N. and Pardthaisong, T. Silpisornkosol, S. Theetranont, C. and Boosiri, B. Chutivongse, S. Jimakorn, P. Virutamasen, P. and Wongsrichanalai, C. Titus-Ernstoff, L. Mosgaard, M. J. and Yeates, D. Chang-Claude, J. Rossing, M. A. Thomas, D. and Weiss, N. Franceschi, S. La Vecchia, C. Adami, H. O. and Magnusson, C. Riman, T. Weiderpass, E. Wolk, A. Brinton, L. A. Freedman, D. M. Hartge, P. Lacey, J. M. Hoover, R. and Schouten, L. J. van den Brandt, P. A. Chantarakul, N. and Koetsawang, S. Rachawat, D. Graff-Iversen, S. Selmer, R. and Bain, C. J. Green, A. C. Purdie, D. M. Siskind, V. Webb, P. M. McCann, S. E. Hannaford, P. Kay, C. Binns, C. W. and Lee, A. H. Zhang, M. Nasca, P. Coogan, P. F. Kelsey, J. Paffenbarger, R. Whittemore, A. Katsouyanni, K. and Trichopoulou, A. Trichopoulos, D. Tzonou, A. Dabancens, A. and Martinez, L. Molina, R. Salas, O. Goodman, M. T. and Laurie, G. Carney, M. E. Wilkens, L. R. Bladstrom, A. and Olsson, H. Ness, R. B. Grisso, J. A. Morgan, M. Wheeler, J. E. Peeters, P. Casagrande, J. Pike, M. C. Ross, R. K. and Wu, A. H. Kumle, M. Lund, E. McGowan, L. Shu, X. O. and Zheng, W. Farley, T. M. M. Holck, S. Meirik, O. and Risch, H. A. Collaborative Grp Epidemiological

Abstract

Background Oral contraceptives were introduced almost 50 years ago, and over 100 million women currently use them. Oral contraceptives can reduce the risk of ovarian cancer, but the eventual public-health effects of this reduction will depend on how long the protection lasts after use ceases. We aimed to assess these effects. Methods Individual data for 23 257 women with ovarian cancer (cases) and 87 303 without ovarian cancer (controls) from 45 epidemiological studies in 21 countries were checked and analysed centrally. The relative risk of ovarian cancer in relation to oral contraceptive use was estimated, stratifying by study, age, parity, and hysterectomy. Findings Overall 7308 (31%) cases and 32 717 (37%) controls had ever used oral contraceptives, for average durations among users of 4 . 4 and 5 . 0 years, respectively. The median year of cancer diagnosis was 1993, when cases were aged an average of 56 years. The longer that women had used oral contraceptives, the greater the reduction in ovarian cancer risk (p

Published
2008

34. Allergy and brain tumors in the INTERPHONE study: pooled results from Australia, Canada, France, Israel, and New Zealand

Author

Turner, MC, Krewski, D, Armstrong, BK, Chetrit, A, Giles, GG, Hours, M, McBride, ML, Parent, M-E, Sadetzki, S, Siemiatycki, J, Woodward, A, Cardis, E, Turner, MC, Krewski, D, Armstrong, BK, Chetrit, A, Giles, GG, Hours, M, McBride, ML, Parent, M-E, Sadetzki, S, Siemiatycki, J, Woodward, A, and Cardis, E

Abstract

PURPOSE: A history of allergy has been inversely associated with several types of cancer although the evidence is not entirely consistent. We examined the association between allergy history and risk of glioma, meningioma, acoustic neuroma, and parotid gland tumors using data on a large number of cases and controls from five INTERPHONE study countries (Australia, Canada, France, Israel, New Zealand), to better understand potential sources of bias in brain tumor case-control studies and to examine associations between allergy and tumor sites where few studies exist. METHODS: A total of 793 glioma, 832 meningioma, 394 acoustic neuroma, and 84 parotid gland tumor cases were analyzed with 2,520 controls recruited during 2000-2004. Conditional logistic regression models were used to obtain odds ratios (ORs) and 95 % confidence intervals (CIs) for associations between self-reported allergy and tumor risk. RESULTS: A significant inverse association was observed between a history of any allergy and glioma (OR = 0.73, 95 % CI 0.60-0.88), meningioma (OR = 0.77, 95 % CI 0.63-0.93), and acoustic neuroma (OR = 0.64, 95 % CI 0.49-0.83). Inverse associations were also observed with specific allergic conditions. However, inverse associations with asthma and hay fever strengthened with increasing age of allergy onset and weakened with longer time since onset. No overall association was observed for parotid gland tumors (OR = 1.21, 95 % CI 0.73-2.02). CONCLUSIONS: While allergy history might influence glioma, meningioma, and acoustic neuroma risk, the observed associations could be due to information or selection bias or reverse causality.

Published
2013

35. Ovarian Cancer and Body Size : Individual Participant Meta-Analysis Including 25,157 Women with Ovarian Cancer from 47 Epidemiological Studies

Author

Beral, V., Hermon, C., Peto, R., Reeves, G., Brinton, L., Marchbanks, P., Negri, E., Ness, R., Peeters, P. H. M., Vessey, M., Calle, E. E., Gapstur, S. M., Patel, A. V., Dal Maso, L., Talamini, R., Chetrit, A., Hirsh-Yechezkel, G., Lubin, F., Sadetzki, S., Allen, N., Bull, D., Callaghan, K., Crossley, B., Gaitskell, K., Goodill, A., Green, J., Key, T., Moser, K., Collins, R., Doll, R., Gonzalez, C. A., Lee, N., Ory, H. W., Peterson, H. B., Wingo, P. A., Martin, N., Pardthaisong, T., Silpisornkosol, S., Theetranont, C., Boosiri, B., Chutivongse, S., Jimakorn, P., Virutamasen, P., Wongsrichanalai, C., Tjonneland, A., Titus-Ernstoff, L., Byers, T., Rohan, T., Mosgaard, B. J., Yeates, D., Freudenheim, J. L., Chang-Claude, J., Kaaks, R., Anderson, K. E., Folsom, A., Robien, K., Rossing, M. A., Thomas, D. B., Weiss, N. S., Riboli, E., Clavel-Chapelon, F., Cramer, D., Hankinson, S. E., Tworoger, S. S., Franceschi, S., La Vecchia, C., Magnusson, C., Riman, T., Weiderpass, E., Wolk, A., Schouten, L. J., van den Brandt, P. A., Chantarakul, N., Koetsawang, S., Rachawat, D., Palli, D., Black, A., de Gonzalez, A. Berrington, Freedman, D. M., Hartge, P., Hsing, A. W., Lacey, J. V., Jr., Hoover, R. N., Schairer, C., Graff-Iversen, S., Selmer, R., Bain, C. J., Green, A. C., Purdie, D. M., Siskind, V., Webb, P. M., McCann, S. E., Hannaford, P., Kay, C., Binns, C. W., Lee, A. H., Zhang, M., Ness, R. B., Nasca, P., Coogan, P. F., Palmer, J. R., Rosenberg, L., Kelsey, J., Paffenbarger, R., Whittemore, A., Katsouyanni, K., Trichopoulou, A., Trichopoulos, D., Tzonou, A., Dabancens, A., Martinez, L., Molina, R., Salas, O., Goodman, M. T., Lurie, G., Carney, M. E., Wilkens, L. R., Hartman, L., Manjer, J., Olsson, H., Grisso, J. A., Morgan, M., Wheeler, J. E., Casagrande, J., Pike, M. C., Ross, R. K., Wu, A. H., Miller, A. B., Kumle, M., Lund, E., McGowan, L., Shu, X. O., Zheng, W., Farley, T. M. M., Holck, S., Meirik, O., Risch, H. A., Beral, V., Hermon, C., Peto, R., Reeves, G., Brinton, L., Marchbanks, P., Negri, E., Ness, R., Peeters, P. H. M., Vessey, M., Calle, E. E., Gapstur, S. M., Patel, A. V., Dal Maso, L., Talamini, R., Chetrit, A., Hirsh-Yechezkel, G., Lubin, F., Sadetzki, S., Allen, N., Bull, D., Callaghan, K., Crossley, B., Gaitskell, K., Goodill, A., Green, J., Key, T., Moser, K., Collins, R., Doll, R., Gonzalez, C. A., Lee, N., Ory, H. W., Peterson, H. B., Wingo, P. A., Martin, N., Pardthaisong, T., Silpisornkosol, S., Theetranont, C., Boosiri, B., Chutivongse, S., Jimakorn, P., Virutamasen, P., Wongsrichanalai, C., Tjonneland, A., Titus-Ernstoff, L., Byers, T., Rohan, T., Mosgaard, B. J., Yeates, D., Freudenheim, J. L., Chang-Claude, J., Kaaks, R., Anderson, K. E., Folsom, A., Robien, K., Rossing, M. A., Thomas, D. B., Weiss, N. S., Riboli, E., Clavel-Chapelon, F., Cramer, D., Hankinson, S. E., Tworoger, S. S., Franceschi, S., La Vecchia, C., Magnusson, C., Riman, T., Weiderpass, E., Wolk, A., Schouten, L. J., van den Brandt, P. A., Chantarakul, N., Koetsawang, S., Rachawat, D., Palli, D., Black, A., de Gonzalez, A. Berrington, Freedman, D. M., Hartge, P., Hsing, A. W., Lacey, J. V., Jr., Hoover, R. N., Schairer, C., Graff-Iversen, S., Selmer, R., Bain, C. J., Green, A. C., Purdie, D. M., Siskind, V., Webb, P. M., McCann, S. E., Hannaford, P., Kay, C., Binns, C. W., Lee, A. H., Zhang, M., Ness, R. B., Nasca, P., Coogan, P. F., Palmer, J. R., Rosenberg, L., Kelsey, J., Paffenbarger, R., Whittemore, A., Katsouyanni, K., Trichopoulou, A., Trichopoulos, D., Tzonou, A., Dabancens, A., Martinez, L., Molina, R., Salas, O., Goodman, M. T., Lurie, G., Carney, M. E., Wilkens, L. R., Hartman, L., Manjer, J., Olsson, H., Grisso, J. A., Morgan, M., Wheeler, J. E., Casagrande, J., Pike, M. C., Ross, R. K., Wu, A. H., Miller, A. B., Kumle, M., Lund, E., McGowan, L., Shu, X. O., Zheng, W., Farley, T. M. M., Holck, S., Meirik, O., and Risch, H. A.

Abstract

Background: Only about half the studies that have collected information on the relevance of women's height and body mass index to their risk of developing ovarian cancer have published their results, and findings are inconsistent. Here, we bring together the worldwide evidence, published and unpublished, and describe these relationships. Methods and Findings: Individual data on 25,157 women with ovarian cancer and 81,311 women without ovarian cancer from 47 epidemiological studies were collected, checked, and analysed centrally. Adjusted relative risks of ovarian cancer were calculated, by height and by body mass index. Ovarian cancer risk increased significantly with height and with body mass index, except in studies using hospital controls. For other study designs, the relative risk of ovarian cancer per 5 cm increase in height was 1.07 (95% confidence interval [CI], 1.05-1.09; p<0.001); this relationship did not vary significantly by women's age, year of birth, education, age at menarche, parity, menopausal status, smoking, alcohol consumption, having had a hysterectomy, having first degree relatives with ovarian or breast cancer, use of oral contraceptives, or use of menopausal hormone therapy. For body mass index, there was significant heterogeneity (p<0.001) in the findings between ever-users and never-users of menopausal hormone therapy, but not by the 11 other factors listed above. The relative risk for ovarian cancer per 5 kg/m(2) increase in body mass index was 1.10 (95% CI, 1.07-1.13; p<0.001) in never-users and 0.95 (95% CI, 0.92-0.99; p = 0.02) in ever-users of hormone therapy. Conclusions: Ovarian cancer is associated with height and, among never-users of hormone therapy, with body mass index. In high-income countries, both height and body mass index have been increasing in birth cohorts now developing the disease. If all other relevant factors had remained constant, then these increases in height and weight would be associated with

Published
2012
Full Text
View/download PDF

36. A new approach to blood pressure measurement in the primary care setting

Author

Kershenbaum, A, Sadetzki, S, Chetrit, A, Fuchs, Z, Bott-Kanner, G, Rosenfeld, J, and Modan, B

Subjects
Adult, Aged, 80 and over, Male, Observer Variation, Blood Pressure, Blood Pressure Determination, Equipment Design, Middle Aged, Sensitivity and Specificity, Hypertension, Humans, Female, Family Practice, Research Article, Aged
Abstract

In this study, a method of taking one blood pressure reading using a sphygmomanometer was compared with a method of taking multiple successive readings using an automatic device. With multiple readings the blood pressure tended to be lower and fewer patients were classified as hypertensive. Using an automatic blood pressure recording device seems to be a practical way of achieving multiple readings in a busy clinic setting.

Published
2000

37. Radiation-induced Chandler's syndrome

Author

Orna Geyer, Neufelder M, Michaeli-Cohen A, Lazar M, Sadetzki S, and Modan B

Subjects
Neoplasms, Radiation-Induced, Iris Diseases, Radiotherapy, Corneal Edema, Humans, Female, Glaucoma, Syndrome, Middle Aged, Radiation Injuries, Tinea Capitis
Published
2000

38. Brain tumor epidemiology : Consensus from the Brain Tumor Epidemiology Consortium

Author

Bondy, M L, Scheurer, M E, Malmer, Beatrice, Barnholtz-Sloan, J S, Davis, F G, Il'yasova, D, Kruchko, C, McCarthy, B J, Rajaraman, P, Schwartzbaum, J A, Sadetzki, S, Schlehofer, B, Tihan, T, Wiemels, J L, Wrensch, M, Buffler, P A, Bondy, M L, Scheurer, M E, Malmer, Beatrice, Barnholtz-Sloan, J S, Davis, F G, Il'yasova, D, Kruchko, C, McCarthy, B J, Rajaraman, P, Schwartzbaum, J A, Sadetzki, S, Schlehofer, B, Tihan, T, Wiemels, J L, Wrensch, M, and Buffler, P A

Abstract

Epidemiologists in the Brain Tumor Epidemiology Consortium (BTEC) have prioritized areas for further research. Although many risk factors have been examined over the past several decades, there are few consistent findings, possibly because of small sample sizes in individual studies and differences between studies in patients, tumor types, and methods of classification. Individual studies generally have lacked samples of sufficient size to examine interactions. A major priority based on available evidence and technologies includes expanding research in genetics and molecular epidemiology of brain tumors. BTEC has taken an active role in Promoting understudied groups, such as pediatric brain tumors; the etiology of rare glioma subtypes, such as oligodendroglioma; and meningioma, which, although it is not uncommon, has only recently, been registered systematically in the United States. There also is a pressing need for more researchers, especially junior investigators, to study brain tumor epidemiology. However, relatively poor funding for brain tumor research has made it difficult to encourage careers in this area. In this report, BTEC epidemiologists reviewed the groups Consensus oil the Current state of scientific findings, and they present a consensus oil research priorities to identify which important areas the science should move to address.

Published
2008
Full Text
View/download PDF

41. Occupational chemical exposures and meningioma

Author

MacCalman, L., primary, van Tongeren, M., additional, Benke, G., additional, Fleming, S., additional, McLean, D., additional, Krewski, D., additional, Parent, M.-E., additional, Sadetzki, S., additional, Schlehofer, B., additional, Siemiatycki, J., additional, Cardis, E., additional, Kincl, L., additional, and Richardson, L., additional

Published
2011
Full Text
View/download PDF

42. INTEROCC study: occupational exposures and risk of glioma brain tumours

Author

Fleming, S., primary, Benke, G., additional, Hours, M., additional, Lavoue, J., additional, Parent, M.-E., additional, Siemiatycki, J., additional, van Tongeren, M., additional, Kincl, L., additional, Krewski, D., additional, McLean, D., additional, Richardson, L., additional, Sadetzki, S., additional, Schlehofer, B., additional, and Cardis, E., additional

Published
2011
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results